聚普瑞锌联合基于克拉霉素三联疗法治疗幽门螺杆菌相关性胃炎的效果(1)
【摘要】 目的：探討聚普瑞锌联合基于克拉霉素三联疗法治疗幽门螺杆菌相关性胃炎的效果及安全性。方法：研究选取2014年1月-2015年6月笔者所在医院就诊的202例Hp相关性胃炎患者。用乱数表法将全部研究对象随机分为两组。观察组106例，对照组96例。对照组奥美拉唑20 mg+阿莫西林1 g+克拉霉素0.5 g，2次/d。观察组聚普瑞锌75 mg+奥美拉唑20 mg+阿莫西林1 g+克拉霉素0.5 g，2次/d。14 d为一疗程。对比两组Hp根除率、总愈合率及不良反应发生情况。结果：观察组Hp根除率81.1%(86/106)，对照组Hp根除率64.6%(62/96)，差异有统计学意义(P<0.05)。观察组总愈合率为89.62%，明显高于对照组的71.88%，差异有统计学意义(P<0.05)。两组均无严重不良反应发生。观察组和对照组不良反应发生率分别为2.83%、2.08%，差异无统计学意义(P>0.05)。结论：聚普瑞锌联合基于克拉霉素三联疗法可显著提高Hp根除率，提高溃疡愈合率，不良反应少而轻，值得临床推广应用。
【关键词】 聚普瑞锌； 克拉霉素； 三联疗法； 幽门螺杆菌； 胃炎
doi：10.14033/j.cnki.cfmr.2018.11.007 文献标识码 B 文章编号 1674-6805(2018)11-0015-02
Treatment of Helicobacter Pylori-associated Gastritis by Combination of Polaprezinc and Clarithromycin Triple Therapy/HE Chunsheng，JIN Feng，SHI Jin.//Chinese and Foreign Medical Research，2018，16(11)：15-16
【Abstract】 Objective：To investigate the efficacy and safety of Polaprezinc combined with Clarithromycin triple therapy in the treatment of Helicobacter pylori-associated gastritis.Method：From January 2014 to June 2015，202 patients with Hp-related gastritis were enrolled in our hospital.All the subjects were randomly divided into two groups.The observation group 106 cases，the control group 96 cases.The control group was taken Omeprazole 20 mg+Amoxicillin 1 g+Clarithromycin 0.5 g，2 times a day.The observation group was taken Polyplorein 75 mg+Omeprazole 20 mg+Amoxicillin 1 g+Clarithromycin 0.5 g，2 times a day.14 d for a course of treatment.Hp eradication rate，total healing rate and adverse reaction occurred in both groups were compared.Result：The eradication rate of Hp was 81.1%(86/106)，and the eradication rate of Hp in the control group was 64.6%(62/96)，the difference was statistically significant(P<0.05).The total healing rate was 89.62% in the observation group，was significantly higher than that in the control group(71.88%)，the difference was statistically significant(P<0.05).No serious adverse events occurred in both groups.The incidence of adverse reactions in the observation group and the control group was 2.83% and 2.08% respectively.There was no significant difference between the two groups(P>0.05).Conclusion：The combination of Polaprezinc combined with Clarithromycin triple therapy can significantly improve the eradication rate of Hp，improve ulcer healing rate，less adverse reactions，it is worthy of clinical application.
【Key words】 Polaprezinc； Clarithromycin； Triple therapy； Helicobacter pylori； Gastritis
First-author’s address：People’s Liberation Army No.476 Hospital，Fuzhou 350002，China, http://www.100md.com(何春生 金峰 石晋)
【关键词】 聚普瑞锌； 克拉霉素； 三联疗法； 幽门螺杆菌； 胃炎
doi：10.14033/j.cnki.cfmr.2018.11.007 文献标识码 B 文章编号 1674-6805(2018)11-0015-02
Treatment of Helicobacter Pylori-associated Gastritis by Combination of Polaprezinc and Clarithromycin Triple Therapy/HE Chunsheng，JIN Feng，SHI Jin.//Chinese and Foreign Medical Research，2018，16(11)：15-16
【Abstract】 Objective：To investigate the efficacy and safety of Polaprezinc combined with Clarithromycin triple therapy in the treatment of Helicobacter pylori-associated gastritis.Method：From January 2014 to June 2015，202 patients with Hp-related gastritis were enrolled in our hospital.All the subjects were randomly divided into two groups.The observation group 106 cases，the control group 96 cases.The control group was taken Omeprazole 20 mg+Amoxicillin 1 g+Clarithromycin 0.5 g，2 times a day.The observation group was taken Polyplorein 75 mg+Omeprazole 20 mg+Amoxicillin 1 g+Clarithromycin 0.5 g，2 times a day.14 d for a course of treatment.Hp eradication rate，total healing rate and adverse reaction occurred in both groups were compared.Result：The eradication rate of Hp was 81.1%(86/106)，and the eradication rate of Hp in the control group was 64.6%(62/96)，the difference was statistically significant(P<0.05).The total healing rate was 89.62% in the observation group，was significantly higher than that in the control group(71.88%)，the difference was statistically significant(P<0.05).No serious adverse events occurred in both groups.The incidence of adverse reactions in the observation group and the control group was 2.83% and 2.08% respectively.There was no significant difference between the two groups(P>0.05).Conclusion：The combination of Polaprezinc combined with Clarithromycin triple therapy can significantly improve the eradication rate of Hp，improve ulcer healing rate，less adverse reactions，it is worthy of clinical application.
【Key words】 Polaprezinc； Clarithromycin； Triple therapy； Helicobacter pylori； Gastritis
First-author’s address：People’s Liberation Army No.476 Hospital，Fuzhou 350002，China, http://www.100md.com(何春生 金峰 石晋)